Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Analysts fell to the sidelines weighing in on Moderna (MRNA – Research Report) and Twist Bioscience (TWST – Research Report) with neutral ratings, indicating that the experts ...

JPMorgan raised the firm’s price target on Apellis (APLS) to $37 from $35 and keeps an Overweight rating on the shares. The firm updated the ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD ...